Matches in SemOpenAlex for { <https://semopenalex.org/work/W2496005978> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2496005978 endingPage "514" @default.
- W2496005978 startingPage "514" @default.
- W2496005978 abstract "PURPOSE: We investigated the association between running and overall cancer mortality. METHODS: Participants were 52,917 adults aged 18-100 years (mean age, 44), who received a preventive medical examination during 1974-2002 at the Cooper Clinic. At baseline, all participants were free of myocardial infarction, stroke, and cancer. Running was assessed on a medical history questionnaire. Participants were classified into 6 groups: nonrunners and 5 quintiles of weekly running amount, time, distance, and frequency. Mortality follow-up was through 2003 using the National Death Index. Cox regression models included baseline age, sex, examination year, smoking status, heavy alcohol drinking, levels of other physical activities, and each running characteristic. RESULTS: During an average follow-up of 14.6 years, 1,193 cancer deaths occurred. Compared with nonrunners, runners (24% of participants) had 21% lower risk of cancer mortality with the hazard ratio (HR) and 95% confidence interval (CI) of 0.79 and 0.68-0.92, respectively. HRs (95% CIs) of cancer mortality were 0.72 (0.53-0.99), 0.78 (0.58-1.04), 0.87 (0.65-1.17), 0.78 (0.58-1.06), and 0.80 (0.58-1.16) in 1-505, 506-812, 813-1,199, 1,200-1,839, and ≥1,840 MET-min/week of running; 0.72 (0.52-0.99), 0.81 (0.60-1.07), 0.75 (0.55-1.04), 0.92 (0.69-1.22), and 0.75 (0.54-1.04) in 1-50, 51-80, 81-119, 120-175, and ≥176 min/week; 0.69 (0.50-0.95), 0.83 (0.61-1.12), 0.80 (0.60-1.06), 0.85 (0.62-1.17), and 0.80 (0.58-1.09) in 1-5, 6-8, 9-12, 13-19, and ≥20 miles/week; 0.52 (0.32-0.83), 0.93 (0.70-1.24), 0.78 (0.59-1.03), 0.87 (0.67-1.13), and 0.73 (0.52-1.02) in 1-2, 3, 4, 5, and ≥6 times/week, respectively, compared with no running. Among runners, there were no significant differences in cancer mortality across quintiles of running doses. Compared with no running, weekly running even <250 MET-min/week and <30 min/week were associated with 53% (HR: 0.47, 95% CI: 0.23-0.93) and 59% (HR: 0.41, 95% CI: 0.17-0.99) lower risks of cancer mortality, respectively. CONCLUSION: This study highlights that running even less than half of the current minimum doses of vigorous-intensity aerobic activity, which is 500 MET-min/week or 75 min/week, is sufficient for substantial cancer mortality benefits. Supported by NIH Grant AG06945, HL62508, and DK088195." @default.
- W2496005978 created "2016-08-23" @default.
- W2496005978 creator A5032577296 @default.
- W2496005978 creator A5039892878 @default.
- W2496005978 creator A5054171427 @default.
- W2496005978 creator A5057947870 @default.
- W2496005978 creator A5059582018 @default.
- W2496005978 date "2016-05-01" @default.
- W2496005978 modified "2023-09-27" @default.
- W2496005978 title "Leisure-time Running And All-cause Cancer Mortality" @default.
- W2496005978 doi "https://doi.org/10.1249/01.mss.0000486547.49506.e5" @default.
- W2496005978 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27360699" @default.
- W2496005978 hasPublicationYear "2016" @default.
- W2496005978 type Work @default.
- W2496005978 sameAs 2496005978 @default.
- W2496005978 citedByCount "1" @default.
- W2496005978 countsByYear W24960059782019 @default.
- W2496005978 crossrefType "journal-article" @default.
- W2496005978 hasAuthorship W2496005978A5032577296 @default.
- W2496005978 hasAuthorship W2496005978A5039892878 @default.
- W2496005978 hasAuthorship W2496005978A5054171427 @default.
- W2496005978 hasAuthorship W2496005978A5057947870 @default.
- W2496005978 hasAuthorship W2496005978A5059582018 @default.
- W2496005978 hasConcept C121608353 @default.
- W2496005978 hasConcept C126322002 @default.
- W2496005978 hasConcept C144024400 @default.
- W2496005978 hasConcept C149923435 @default.
- W2496005978 hasConcept C1862650 @default.
- W2496005978 hasConcept C207103383 @default.
- W2496005978 hasConcept C2777654188 @default.
- W2496005978 hasConcept C2779874844 @default.
- W2496005978 hasConcept C2908647359 @default.
- W2496005978 hasConcept C44249647 @default.
- W2496005978 hasConcept C500558357 @default.
- W2496005978 hasConcept C50382708 @default.
- W2496005978 hasConcept C71924100 @default.
- W2496005978 hasConcept C99454951 @default.
- W2496005978 hasConceptScore W2496005978C121608353 @default.
- W2496005978 hasConceptScore W2496005978C126322002 @default.
- W2496005978 hasConceptScore W2496005978C144024400 @default.
- W2496005978 hasConceptScore W2496005978C149923435 @default.
- W2496005978 hasConceptScore W2496005978C1862650 @default.
- W2496005978 hasConceptScore W2496005978C207103383 @default.
- W2496005978 hasConceptScore W2496005978C2777654188 @default.
- W2496005978 hasConceptScore W2496005978C2779874844 @default.
- W2496005978 hasConceptScore W2496005978C2908647359 @default.
- W2496005978 hasConceptScore W2496005978C44249647 @default.
- W2496005978 hasConceptScore W2496005978C500558357 @default.
- W2496005978 hasConceptScore W2496005978C50382708 @default.
- W2496005978 hasConceptScore W2496005978C71924100 @default.
- W2496005978 hasConceptScore W2496005978C99454951 @default.
- W2496005978 hasLocation W24960059781 @default.
- W2496005978 hasOpenAccess W2496005978 @default.
- W2496005978 hasPrimaryLocation W24960059781 @default.
- W2496005978 hasRelatedWork W2071306276 @default.
- W2496005978 hasRelatedWork W2121348648 @default.
- W2496005978 hasRelatedWork W2159483167 @default.
- W2496005978 hasRelatedWork W2314052727 @default.
- W2496005978 hasRelatedWork W2803714001 @default.
- W2496005978 hasRelatedWork W2912396396 @default.
- W2496005978 hasRelatedWork W2920989823 @default.
- W2496005978 hasRelatedWork W3122724326 @default.
- W2496005978 hasRelatedWork W4200305071 @default.
- W2496005978 hasRelatedWork W4212959990 @default.
- W2496005978 hasVolume "48" @default.
- W2496005978 isParatext "false" @default.
- W2496005978 isRetracted "false" @default.
- W2496005978 magId "2496005978" @default.
- W2496005978 workType "article" @default.